keyword
MENU ▼
Read by QxMD icon Read
search

Blood test for lung cancer

keyword
https://www.readbyqxmd.com/read/27906860/liquid-biopsy-for-early-detection-of-lung-cancer
#1
Paul Hofman
PURPOSE OF REVIEW: The possibility of complete recovery for a lung cancer patient depends on very early diagnosis, as it allows total surgical resection. Screening for this cancer in a high-risk population can be performed using a radiological approach, but this holds a certain number of limitations. Liquid biopsy could become an alternative and complementary screening approach to chest imaging for early diagnosis of lung cancer. RECENT FINDINGS: Several circulating biomarkers indicative of lung cancer can be investigated in blood, such as circulating tumor cells, circulating free nucleic acids (RNA and DNA) and proteins...
January 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27898657/serum-proteomic-test-in-advanced-non-squamous-non-small-cell-lung-cancer-treated-in-first-line-with-standard-chemotherapy
#2
F Grossi, E Rijavec, C Genova, G Barletta, F Biello, C Maggioni, G Burrafato, C Sini, M G Dal Bello, K Meyer, J Roder, H Roder, J Grigorieva
BACKGROUND: VeriStrat is a blood-based proteomic test with predictive and prognostic significance in second-line treatments for non-small cell lung cancer (NSCLC). This trial was designed to investigate the role of VeriStrat in first-line treatment of advanced NSCLC with standard chemotherapy. Here we present the results for 76 non-squamous patients treated with a combination of carboplatin or cisplatin with pemetrexed. METHODS: The test-assigned classifications of VeriStrat Good or VeriStrat Poor to samples collected at baseline...
November 29, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27891193/in-epithelial-cancers-aberrant-col17a1-promoter-methylation-predicts-its-misexpression-and-increased-invasion
#3
Pulari U Thangavelu, Tibor Krenács, Eloise Dray, Pascal H G Duijf
BACKGROUND: Metastasis is a leading cause of death among cancer patients. In the tumor microenvironment, altered levels of extracellular matrix proteins, such as collagens, can facilitate the first steps of cancer cell metastasis, including invasion into surrounding tissue and intravasation into the blood stream. However, the degree of misexpression of collagen genes in tumors remains understudied, even though this knowledge could greatly facilitate the development of cancer treatment options aimed at preventing metastasis...
2016: Clinical Epigenetics
https://www.readbyqxmd.com/read/27889655/a-prediction-model-based-on-biomarkers-and-clinical-characteristics-for-detection-of-lung-cancer-in-pulmonary-nodules
#4
Jie Ma, Maria A Guarnera, Wenxian Zhou, HongBin Fang, Feng Jiang
Lung cancer early detection by low-dose computed tomography (LDCT) can reduce the mortality. However, LDCT increases the number of indeterminate pulmonary nodules (PNs), whereas 95% of the PNs are ultimately false positives. Modalities for specifically distinguishing between malignant and benign PNs are urgently needed. We previously identified a panel of peripheral blood mononucleated cell (PBMC)-miRNA (miRs-19b-3p and -29b-3p) biomarkers for lung cancer. This study aimed to evaluate efficacy of integrating biomarkers and clinical and radiological characteristics of smokers for differentiating malignant from benign PNs...
November 24, 2016: Translational Oncology
https://www.readbyqxmd.com/read/27876017/increased-wnt5a-in-squamous-cell-lung-carcinoma-inhibits-endothelial-cell-motility
#5
J Rapp, E Kiss, M Meggyes, E Szabo-Meleg, D Feller, G Smuk, T Laszlo, V Sarosi, T F Molnar, K Kvell, J E Pongracz
BACKGROUND: Angiogenesis is important both in normal tissue function and disease and represents a key target in lung cancer (LC) therapy. Unfortunately, the two main subtypes of non-small-cell lung cancers (NSCLC) namely, adenocarcinoma (AC) and squamous cell carcinoma (SCC) respond differently to anti-angiogenic e.g. anti-vascular endothelial growth factor (VEGF)-A treatment with life-threatening side effects, often pulmonary hemorrhage in SCC. The mechanisms behind such adverse reactions are still largely unknown, although peroxisome proliferator activator receptor (PPAR) gamma as well as Wnt-s have been named as molecular regulators of the process...
November 23, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27869802/molecular-analysis-of-circulating-tumor-cells-identifies-distinct-copy-number-profiles-in-patients-with-chemosensitive-and-chemorefractory-small-cell-lung-cancer
#6
Louise Carter, Dominic G Rothwell, Barbara Mesquita, Christopher Smowton, Hui Sun Leong, Fabiola Fernandez-Gutierrez, Yaoyong Li, Deborah J Burt, Jenny Antonello, Christopher J Morrow, Cassandra L Hodgkinson, Karen Morris, Lynsey Priest, Mathew Carter, Crispin Miller, Andrew Hughes, Fiona Blackhall, Caroline Dive, Ged Brady
In most patients with small-cell lung cancer (SCLC)-a metastatic, aggressive disease-the condition is initially chemosensitive but then relapses with acquired chemoresistance. In a minority of patients, however, relapse occurs within 3 months of initial treatment; in these cases, disease is defined as chemorefractory. The molecular mechanisms that differentiate chemosensitive from chemorefractory disease are currently unknown. To identify genetic features that distinguish chemosensitive from chemorefractory disease, we examined copy-number aberrations (CNAs) in circulating tumor cells (CTCs) from pretreatment SCLC blood samples...
November 21, 2016: Nature Medicine
https://www.readbyqxmd.com/read/27867087/a-quantitative-immunoassay-for-lung-cancer-biomarker-ciz1b-in-patient-plasma
#7
Dawn Coverley, Gillian Higgins, Daniel West, Oliver T Jackson, Adam Dowle, Aidan Haslam, Eve Ainscough, Rebecca Chalkley, John White
OBJECTIVES: Non-invasive tests for early detection of lung cancer are an important unmet clinical need. CIZ1b plasma biomarker can discriminate stage 1 lung cancer from within high-risk groups with clinically useful accuracy, with ROC AUCs in excess of 0.9 for two independent retrospective cohorts, and could therefore meet this need. Our aim was to characterise the native state of the biomarker and develop a quantitative immunoassay. DESIGN AND METHODS: Selective denaturation, preparative electrophoresis and mass spectrometry of human plasma were used to characterise the biomarker and interaction partners...
November 17, 2016: Clinical Biochemistry
https://www.readbyqxmd.com/read/27849557/honokiol-decreases-lung-cancer-metastasis-through-inhibition-of-the-stat3-signaling-pathway
#8
Jing Pan, Yongik Lee, Qi Zhang, Donghai Xiong, Wan C Tina, Yian Wang, Ming You
Lung cancer is the leading cause of cancer death in the United States. Metastasis to lymph nodes (LN) and distal organs, especially brain, leads to severe complications and death. Preventing lung cancer development and metastases is important strategy to reduce lung cancer mortality. Honokiol (HNK), a natural compound presents in extracts of magnolia bark, has a favorable bioavailability profile and recently has been shown to readily cross the blood-brain barrier (BBB). In the current study, we evaluated the anti-metastatic effects of HNK in both the LN and brain mouse models of lung tumor metastasis...
November 14, 2016: Cancer Prevention Research
https://www.readbyqxmd.com/read/27846378/tumor-delineation-and-quantitative-assessment-of-glucose-metabolic-rate-within-histologic-subtypes-of-non-small-cell-lung-cancer-by-using-dynamic-18-f-fluorodeoxyglucose-pet
#9
Tineke W H Meijer, Lioe-Fee de Geus-Oei, Eric P Visser, Wim J G Oyen, Monika G Looijen-Salamon, Dimitris Visvikis, Ad F T M Verhagen, Johan Bussink, Dennis Vriens
Purpose To assess whether dynamic fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) has added value over static (18)F-FDG PET for tumor delineation in non-small cell lung cancer (NSCLC) radiation therapy planning by using pathology volumes as the reference standard and to compare pharmacokinetic rate constants of (18)F-FDG metabolism, including regional variation, between NSCLC histologic subtypes. Materials and Methods The study was approved by the institutional review board. Patients gave written informed consent...
November 15, 2016: Radiology
https://www.readbyqxmd.com/read/27830712/a-dynamic-in-vivo-like-organotypic-blood-brain-barrier-model-to-probe-metastatic-brain-tumors
#10
Hui Xu, Zhongyu Li, Yue Yu, Saman Sizdahkhani, Winson S Ho, Fangchao Yin, Li Wang, Guoli Zhu, Min Zhang, Lei Jiang, Zhengping Zhuang, Jianhua Qin
The blood-brain barrier (BBB) restricts the uptake of many neuro-therapeutic molecules, presenting a formidable hurdle to drug development in brain diseases. We proposed a new and dynamic in vivo-like three-dimensional microfluidic system that replicates the key structural, functional and mechanical properties of the blood-brain barrier in vivo. Multiple factors in this system work synergistically to accentuate BBB-specific attributes-permitting the analysis of complex organ-level responses in both normal and pathological microenvironments in brain tumors...
November 10, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27826532/kras-mutations-in-the-circulating-free-dna-cfdna-of-non-small-cell-lung-cancer-nsclc-patients
#11
REVIEW
Mónica Garzón, Sergi Villatoro, Cristina Teixidó, Clara Mayo, Alejandro Martínez, Maria de Los Llanos Gil, Santiago Viteri, Daniela Morales-Espinosa, Rafael Rosell
Circulating free DNA (cfDNA) is obtained from serum or plasma by non-invasive methods such as a simple blood draw, a technique known as "liquid biopsy". Genetic analyses of driver alterations in cfDNA have proved very effective to predict survival and treatment response of cancer patients according to tumoral cfDNA burden in blood. Non-small cell lung cancer (NSCLC) patients with higher concentration of tumoral cfDNA in blood have, on average, shorter progression-free survival (PFS) and overall survival (OS)...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826531/next-generation-sequencing-techniques-in-liquid-biopsy-focus-on-non-small-cell-lung-cancer-patients
#12
REVIEW
Umberto Malapelle, Pasquale Pisapia, Danilo Rocco, Riccardo Smeraglio, Maria di Spirito, Claudio Bellevicine, Giancarlo Troncone
The advent of genomic based personalized medicine has led to multiple advances in the molecular characterization of many tumor types, such as non-small cell lung cancer (NSCLC). NSCLC is diagnosed in most cases on small tissue samples that may be not always sufficient for EGFR mutational assessment to select patients for first and second generations' tyrosine kinase inhibitors (TKIs) therapy. In patients without tissue availability at presentation, the analysis of cell free DNA (cfDNA) derived from liquid biopsy samples, in particular from plasma, represent an established alternative to provide EGFR mutational testing for treatment decision making...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27809894/interstitial-pneumonia-in-a-patient-treated-with-tas-102-for-metastatic-colorectal-cancer-a-case-report
#13
Hideki Kamei, Nobuya Ishibashi, Masahiko Tanigawa, Keizo Yamaguchi, Masafumi Uchida, Yoshito Akagi
BACKGROUND: TAS-102, a new treatment option for patients with metastatic colorectal cancer that is refractory or intolerant to standard therapies, has been improving survival with acceptable tolerability and adverse events. Adverse hematological events associated with TAS-102 treatment were extensively profiled in the RECOURSE trial, but pulmonary toxicities associated with TAS-102 therapy are distinctly uncommon. In a recent early post-marketing phase vigilance on TAS-102 in Japan, seven cases of pulmonary disease were reported, but patient follow-up in this study was incomplete...
November 3, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27807108/development-of-a-prognostic-survival-algorithm-for-patients-with-metastatic-spine-disease
#14
Nuno Rui Paulino Pereira, Stein J Janssen, Eva van Dijk, Mitchel B Harris, Francis J Hornicek, Marco L Ferrone, Joseph H Schwab
BACKGROUND: Current prognostication models for survival estimation in patients with metastatic spine disease lack accuracy. Identifying new risk factors could improve existing models. We assessed factors associated with survival in patients surgically treated for spine metastases, created a classic scoring algorithm, nomogram, and boosting algorithm, and tested the predictive accuracy of the three created algorithms at estimating survival. METHODS: We included 649 patients from two tertiary care referral centers in this retrospective study (2002 to 2014)...
November 2, 2016: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/27794409/high-met-status-in-non-small-cell-lung-tumors-correlates-with-receptor-phosphorylation-but-not-with-the-serum-level-of-soluble-form
#15
Marie-Christine Copin, Marie Lesaffre, Mélanie Berbon, Louis Doublet, Catherine Leroy, Emmanuelle Tresch, Henri Porte, Jérôme Vicogne, Alexis B Cortot, Eric Dansin, David Tulasne
OBJECTIVES: The receptor tyrosine kinase MET is essential to embryonic development and organ regeneration. Its deregulation is associated with tumorigenesis. While MET gene amplification and mutations leading to MET self-activation concern only a few patients, a high MET level has been found in about half of the non-small cell lung cancers (NSCLCs) tested. How this affects MET activation in tumors is unclear. Also uncertain is the prognostic value, in cancer, of a phenomenon well described in cell models: MET shedding, i...
November 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27753035/digital-pcr-of-genomic-rearrangements-for-monitoring-circulating-tumour-dna
#16
Hongdo Do, Daniel Cameron, Ramyar Molania, Bibhusal Thapa, Gareth Rivalland, Paul L Mitchell, Carmel Murone, Thomas John, Anthony Papenfuss, Alexander Dobrovic
Identifying circulating tumour DNA (ctDNA) for monitoring of cancer therapy is dependent on the development of readily designed, sensitive cancer-specific DNA markers. Genomic rearrangements that are present in the vast majority of cancers provide such markers.Tumour DNA isolated from two fresh-frozen lung tumours underwent whole genome sequencing. Genomic rearrangements were detected using a new computational algorithm, GRIDSS. Four genomic rearrangements from each tumour were chosen for further study using rearrangement-specific primers...
2016: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27749792/multifocal-choroidal-melanoma-in-a-patient-with-germ-line-brca-associated-protein-1-mutation
#17
Raksha Rao, Renelle Pointdujour-Lim, Arupa Ganguly, Carol L Shields
PURPOSE: To report a case of unilateral multifocal melanoma in a patient with germ line BRCA-associated protein 1 mutation. METHODS: Case report. RESULTS: A 67-year-old white woman with a family history of lung and liver cancers developed blurred visual acuity of 20/30 in the left eye. She was discovered to have two independent pigmented choroidal melanomas in the macula and superotemporally, both demonstrating overlying subretinal fluid and orange pigment...
October 4, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27743884/peptide-screen-identifies-a-new-nadph-oxidase-inhibitor-impact-on-cell-migration-and-invasion
#18
Mohamed Mousslim, Alessandra Pagano, Nicolas Andreotti, Françoise Garrouste, Sylvie Thuault, Vincent Peyrot, Fabrice Parat, José Luis, Marcel Culcasi, Sophie Thétiot-Laurent, Sylvia Pietri, Jean-Marc Sabatier, Hervé Kovacic
The NADPH oxidase proteins catalyse the formation of superoxide anion which act as signalling molecules in physiological and pathological processes. Nox1-dependent NADPH oxidase is expressed in heart, lung, colon, blood vessels and brain. Different strategies involving Nox1 inhibition based on diphenylene iodonium derivatives are currently tested for colorectal cancer therapy. Here, after peptides screening on Nox1-dependent NADPH oxidase assay in HT-29 cells, we identify a peptide (referred to as NF02), cell-active, that potently block Nox1-dependent reactive oxygen species generation...
October 12, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27743211/evaluation-of-a-flexible-nota-rgd-kit-solution-using-gallium-68-from-different-68-ge-68-ga-generators-pharmacokinetics-and-biodistribution-in-nonhuman-primates-and-demonstration-of-solitary-pulmonary-nodule-imaging-in-humans
#19
Thomas Ebenhan, Isabel Schoeman, Daniel D Rossouw, Anne Grobler, Biljana Marjanovic-Painter, Judith Wagener, Hendrik G Kruger, Mike M Sathekge, Jan Rijn Zeevaart
PURPOSE: Radiopharmaceuticals containing the motive tripeptide arginyl-glycyl-asparatic acid (RGD) are known to target ανβ3 integrins during tumor angiogenesis. A more generic kit radiolabeling procedure accommodating Ga-68 from different generators was developed for NOTA-RGD and evaluated for its versatile use and safety in subsequent in vivo applications. The [(68)Ga]NOTA-RGD kit was further verified for its expected biodistribution and pharmacokinetics in nonhuman primates and its clinical sensitivity to detect solitary pulmonary nodules (SPN) in cancer patients...
October 14, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/27709284/population-pharmacokinetic-pharmacodynamic-modeling-and-model-based-prediction-of-docetaxel-induced-neutropenia-in-japanese-patients-with-non-small-cell-lung-cancer
#20
Masato Fukae, Yoshimasa Shiraishi, Takeshi Hirota, Yuka Sasaki, Mika Yamahashi, Koichi Takayama, Yoichi Nakanishi, Ichiro Ieiri
PURPOSE: Docetaxel is used to treat many cancers, and neutropenia is the dose-limiting factor for its clinical use. A population pharmacokinetic-pharmacodynamic (PK-PD) model was introduced to predict the development of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer (NSCLC). METHODS: Forty-seven advanced or recurrent Japanese patients with NSCLC were enrolled. Patients received 50 or 60 mg/m(2) docetaxel as monotherapy, and blood samples for a PK analysis were collected up to 24 h after its infusion...
October 5, 2016: Cancer Chemotherapy and Pharmacology
keyword
keyword
24482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"